Post by
Eoganacht on Jun 20, 2024 12:21pm
Making every penny count...
Despite all the management bashing that has gone on on this board, it must be admitted that Theralase has made some canny choices.
Because of limited funds, for their first cancer indication they chose BCG-unresponsive NMIBC which could be commercialized the quickest. As the standard of care treatment for this disease is cystectomy, no phase 3 trial is required. Can you imagine if when the current trial was completed in 2026, Theralase had to begin a costly and time-consuming phase 3?
Next up is GBM and NSCLC, the deadliest and most common forms of cancer respectively, Having demonstrated they can produce a "best in class" treatment for NMIBC they are moving on to tackle the most difficult to treat and the most widespread forms of cancer, together in a single "adaptive" set of trials.
"...Theralase®, subject to the required regulatory approvals, plans to intravenously inject Rutherrin® into patients via a Phase Ib/II adaptive clinical study design, to first determine localization to various cancer cells, including Glio Blastoma Multiforme (“GBM”) and Non-Small Cell Lung Cancer (“NSCLC”) and then in an adaptive design activate Rutherrin® with radiation with the intent of safely and effectively destroying the cancer of interest."
Talk about bang for your buck.
Comment by
Dumbeldorfwhite on Jun 20, 2024 12:29pm
Ok Ben to, that's enough pumping for 1 day, sp almost at 13 cents and will be heading to new lows after the pp. probably single digits
Comment by
Tarbaby on Jun 20, 2024 1:39pm
Good post Eog.. Has Rutherrin been approved for direct injection other than bladder instillation.? If so then do they plan to inject Ru snd apply xray radiation to human subjects.? That would be a Game Changer for sure...
Comment by
Galaxym31 on Jun 20, 2024 2:48pm
Lets be clear there is no shortage of terribly suffering termal victims .